Personal import allowances, compared
What I would check first on personal import allowances is whether the thing being measured moved or whether the way of measuring it moved. Those look identical in a graph.
Coming back to the opening post, because the follow-up matters more than the original answer.
Nothing here is legal advice, and in this subcategory that caveat is doing real work rather than sitting decoratively at the end.
I read post #4 twice before replying, because I had assumed the opposite.
On personal import allowances, I would rather understate and be corrected upward than overstate and be quoted. That is a house style here and it is a good one.
Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).
Read the full topic (10 posts)
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Cross-border purchase within the EU: the actual rules
Posting this under the heading it deserves: Second pass at: Cross-border purchase within the EU: the actual rules Everything below is what sits behind that. The question about Cross-border purchase within…
|
+135 | 139 | 8.7k | 16mo |
|
Revisiting: Language barriers in accessing a prescription abroad
Posting this under the heading it deserves: Revisiting: Language barriers in accessing a prescription abroad Everything below is what sits behind that. Asking about Language barriers in accessing on behalf of…
|
+131 | 148 | 28k | 5mo |
|
About the International category
Country-by-country availability and legality, dated because it changes constantly. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
+6 | 11 | 240 | 22mo |
|
Language barriers in accessing a prescription abroad
Language barriers in accessing a prescription abroad Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about language barriers in accessing in a thread last spring…
|
2 | 22k | 1h | |
|
What changed in 2026, by region
What changed in 2026, by region — that is the question, and I have not found it answered plainly anywhere I have looked. Documenting an access outcome, dated, because everything in this category expires. As…
|
+110 | 122 | 1.4k | 18mo |
Related topics — sharing the tags EMA, MHRA, telehealth
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Coming back to: Cross-border purchase rules within the EU
Cross-border purchase rules within the EU Writing it up because I had to work it out twice and would rather nobody else did. Cross-border purchase rules within — I have the observation and I do not trust my…
|
+12 | 16 | 2.8k | 11mo |
|
Second pass at: When your prescriber and the evidence disagree
Second pass at: When your prescriber and the evidence disagree — setting out what I have, and where I think it stops being reliable. What changes if the standard account of prescriber is wrong? I ask because…
|
+51 | 55 | 9.2k | 2d |
|
MHRA statements, read directly
MHRA statements, read directly Writing it up because I had to work it out twice and would rather nobody else did. Asking about MHRA statements directly, because I have read four threads on it and each…
|
+93 | 101 | 2.2k | 5mo |
|
Second pass at: Import rules for personal quantities, by jurisdiction, dated
Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. Asking what a regulator's document actually…
|
2 | 5k | 11mo | |
|
Discussing something you have already been doing — the long version
Discussing something you have already been doing — the long version Writing it up because I had to work it out twice and would rather nobody else did. A question about how to describe something to a clinician…
|
+14 | 18 | 58k | 12mo |